Summary

BMS-986001 is a novel nucleoside analog reverse-transcriptase inhibitor that, in higher doses, demonstrated comparable efficacy to tenofovir in treatment-naïve HIV-1-infected subjects. This article presents the results of this phase 2b randomized dose trial (active controlled, blinded to BMS-986001) with worldwide recruitment.